Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2004 Feb;59(2):111–115. doi: 10.1136/thorax.2003.011130

Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma

M Delvaux 1, M Henket 1, L Lau 1, P Kange 1, P Bartsch 1, R Djukanovic 1, R Louis 1
PMCID: PMC1746927  PMID: 14760148

Abstract

Background: Inhalation of hypertonic or even isotonic saline during sputum induction may cause bronchospasm in susceptible patients with asthma, despite premedication with 400 µg inhaled salbutamol delivered by pressurised metered dose inhaler (pMDI). The bronchoprotection afforded by additional inhaled salbutamol administered through the ultrasonic nebuliser during sputum induction was investigated.

Methods: Twenty patients with moderate to severe asthma underwent sputum induction by inhaling saline 4.5% (or 0.9% if post-bronchodilation forced expiratory volume in 1 second (FEV1) <65% predicted) for 10 minutes according to two protocols given 1 week apart in random order. At visit A the patients received 400 µg salbutamol administered through a pMDI + spacer 20 minutes before induction while at visit B the premedication was supplemented by 1500 µg nebulised salbutamol inhaled throughout the induction procedure. Both the investigator and the patients were blind to the nebulised solution used. FEV1 was recorded during sputum induction at 1, 3, 5, and 10 minutes. Sputum cell counts and histamine, tryptase and albumin levels in the supernatants were determined.

Results: The mean (SE) maximal reduction in FEV1 over the 10 minute period of sputum induction was 11.7 (2.8)% at visit A, which was significantly greater than at visit B (2.6 (1.2)%; mean difference 9% (95% CI 2.7 to 15.4), p<0.01). Total and differential sputum cell counts as well as albumin, tryptase, and histamine levels did not differ between the two visits.

Conclusion: The addition of inhaled salbutamol through an ultrasonic nebuliser markedly improves bronchoprotection against saline induced bronchoconstriction in patients with moderate to severe asthma undergoing sputum induction without affecting cell counts and inflammatory markers.

Full Text

The Full Text of this article is available as a PDF (286.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. J. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med. 1995 Sep;152(3):838–860. doi: 10.1164/ajrccm.152.3.7663795. [DOI] [PubMed] [Google Scholar]
  2. Bel E. H., Zwinderman A. H., Timmers M. C., Dijkman J. H., Sterk P. J. The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax. 1991 Jan;46(1):9–14. doi: 10.1136/thx.46.1.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cockcroft D. W., Swystun V. A. Functional antagonism: tolerance produced by inhaled beta 2 agonists. Thorax. 1996 Oct;51(10):1051–1056. doi: 10.1136/thx.51.10.1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fahy J. V., Boushey H. A., Lazarus S. C., Mauger E. A., Cherniack R. M., Chinchilli V. M., Craig T. J., Drazen J. M., Ford J. G., Fish J. E. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med. 2001 May;163(6):1470–1475. doi: 10.1164/ajrccm.163.6.9901105. [DOI] [PubMed] [Google Scholar]
  5. Finnerty J. P., Wilmot C., Holgate S. T. Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen. Evidence for the predominant role of histamine. Am Rev Respir Dis. 1989 Sep;140(3):593–597. doi: 10.1164/ajrccm/140.3.593. [DOI] [PubMed] [Google Scholar]
  6. Gajalakshmi Vendhan, Peto Richard, Kanaka Thanjavur Santhanakrishna, Jha Prabhat. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet. 2003 Aug 16;362(9383):507–515. doi: 10.1016/S0140-6736(03)14109-8. [DOI] [PubMed] [Google Scholar]
  7. Joos G. F., O'Connor B., Anderson S. D., Chung F., Cockcroft D. W., Dahlén B., DiMaria G., Foresi A., Hargreave F. E., Holgate S. T. Indirect airway challenges. Eur Respir J. 2003 Jun;21(6):1050–1068. doi: 10.1183/09031936.03.00008403. [DOI] [PubMed] [Google Scholar]
  8. Kips J. C., Pauwels R. A. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med. 2001 Sep 15;164(6):923–932. doi: 10.1164/ajrccm.164.6.2010107. [DOI] [PubMed] [Google Scholar]
  9. Lipworth B. J., Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):88–92. doi: 10.1016/s0091-6749(99)70530-0. [DOI] [PubMed] [Google Scholar]
  10. Louis R., Shute J., Goldring K., Perks B., Lau L. C., Radermecker M., Djukanovic R. The effect of processing on inflammatory markers in induced sputum. Eur Respir J. 1999 Mar;13(3):660–667. doi: 10.1183/09031936.99.13366099. [DOI] [PubMed] [Google Scholar]
  11. Parameswaran K. N., Inman M. D., Ekholm B. P., Morris M. M., Summers E., O'Byrne P. M., Hargreave F. E. Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. Am J Respir Crit Care Med. 1999 Jul;160(1):354–357. doi: 10.1164/ajrccm.160.1.9812035. [DOI] [PubMed] [Google Scholar]
  12. Pin I., Gibson P. G., Kolendowicz R., Girgis-Gabardo A., Denburg J. A., Hargreave F. E., Dolovich J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992 Jan;47(1):25–29. doi: 10.1136/thx.47.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pizzichini M. M., Pizzichini E., Clelland L., Efthimiadis A., Mahony J., Dolovich J., Hargreave F. E. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med. 1997 May;155(5):1501–1508. doi: 10.1164/ajrccm.155.5.9154849. [DOI] [PubMed] [Google Scholar]
  14. Rajakulasingam K., Polosa R., Lau L. C., Church M. K., Holgate S. T., Howarth P. H. Comparative nasal effects of bradykinin and histamine: influence on nasal airways resistance and plasma protein exudation. Thorax. 1993 Apr;48(4):324–329. doi: 10.1136/thx.48.4.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schoeffel R. E., Anderson S. D., Altounyan R. E. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed) 1981 Nov 14;283(6302):1285–1287. doi: 10.1136/bmj.283.6302.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Umeno E., McDonald D. M., Nadel J. A. Hypertonic saline increases vascular permeability in the rat trachea by producing neurogenic inflammation. J Clin Invest. 1990 Jun;85(6):1905–1908. doi: 10.1172/JCI114652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wong H. H., Fahy J. V. Safety of one method of sputum induction in asthmatic subjects. Am J Respir Crit Care Med. 1997 Jul;156(1):299–303. doi: 10.1164/ajrccm.156.1.9610114. [DOI] [PubMed] [Google Scholar]
  18. ten Brinke A., de Lange C., Zwinderman A. H., Rabe K. F., Sterk P. J., Bel E. H. Sputum induction in severe asthma by a standardized protocol: predictors of excessive bronchoconstriction. Am J Respir Crit Care Med. 2001 Sep 1;164(5):749–753. doi: 10.1164/ajrccm.164.5.2009035. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES